Focal adhesion kinase (FAK) inhibitor‐defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K/AKT axis and downstream molecular network
2010 ◽
Vol 23
(2)
◽
pp. 175-184
◽
2020 ◽
2011 ◽
Vol 131
(2)
◽
pp. 287-297
◽